AstraZeneca's EU Lung Cancer Drug Application Withdrawn Amid Mixed Trial Results

AstraZeneca and Daiichi Sankyo withdraw their EU marketing authorization application for datopotamab deruxtecan due to mixed trial results, but remain committed to ongoing research...